טוען...
Human PIV-2 Recombinant Sendai Virus (rSeV) Elicits Durable Immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV
The human parainfluenza viruses (hPIVs) and respiratory syncytial viruses (RSV) are the leading causes of hospitalizations due to respiratory viral disease in infants and young children, but no vaccines are yet available. Here we describe the use of recombinant Sendai viruses (rSeVs) as candidate va...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2744503/ https://ncbi.nlm.nih.gov/pubmed/19200447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2009.01.041 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|